ClotProtect is developing a first-in-class anti-fibrinolytic to improve survival and bleeding outcomes of standard of care, tranexamic acid (TXA). We are developing a small molecule direct, selective plasmin inhibitor that will have greater efficacy than TXA to be delivered intravenously.